The mortality reducing effect of aspirin in colorectal cancer patients: Interpreting the evidence

Cancer Treatment Reviews

Volumn 55, Issue , 2017, Pages 120-127

  Frouws, Martine A ^a   van Herk Sukel, Myrthe P P ^b   Maas, Huub A ^c   Van de Velde, Cornelis J H ^a   Portielje, Johanneke E A ^d   Liefers, Gerrit Jan ^a   Bastiaannet, Esther ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^c Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^d HAGA HOSPITAL   (Netherlands)

Author keywords

Aspirin; Bias; Colorectal cancer; Drug repurposing; Epidemiology

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; DISEASE ASSESSMENT; DRUG EFFICACY; DRUG USE; EVIDENCE BASED MEDICINE; HUMAN; OBSERVATIONAL STUDY; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; EPIDEMIOLOGY; META ANALYSIS (TOPIC); METHODOLOGY; MORTALITY; STATISTICAL BIAS; SURVIVAL RATE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BIAS (EPIDEMIOLOGY); CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); META-ANALYSIS AS TOPIC; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SURVIVAL RATE;

EID: 85016146386     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.12.008     Document Type: Review

References (77)

1. [1] Tsoucalas, G., Karamanou, M., Androutsos, G., Travelling through time with aspirin, a healing companion. Eur J Inflammation 9 (2011), 13–16.
2. [2] Henschke, U.K., Luande, G.J., Choppala, J.D., Aspirin for reducing cancer metastases?. J Natl Med Assoc 69 (1977), 581–584.
3. [3] Coyle, C., Cafferty, F.H., Langley, R.E., Aspirin and colorectal cancer prevention and treatment: is it for everyone?. Current Colorectal Cancer Rep, 2016.
4. [4] Sullivan, R., Alatise, O.I., Anderson, B.O., Audisio, R., Autier, P., Aggarwal, A., et al. Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncol 16 (2015), 1193–1224.
5. [5] Li, P., Wu, H., Zhang, H., Shi, Y., Xu, J., Ye, Y., et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut 64 (2015), 1419–1425.
6. [6] Ye, X.F., Wang, J., Shi, W.T., He, J., Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies. Br J Cancer 111 (2014), 2172–2179.
7. [7] Elwood, P.C., Morgan, G., Pickering, J.E., Galante, J., Weightman, A.L., Morris, D., et al. Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies. PLoS One, 11, 2016, e0152402.
8. [8] Paleari, L., Puntoni, M., Clavarezza, M., DeCensi, M., Cuzick, J., DeCensi, A., PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. a systematic review and meta-analysis of epidemiological studies. Clin Oncol (R Coll Radiol), 2015.
9. [9] Bains, S.J., Mahic, M., Myklebust, T.A., Smastuen, M.C., Yaqub, S., Dorum, L.M., et al. Aspirin as secondary prevention in patients with colorectal cancer: an unselected population-based study. J Clin Oncol 34 (2016), 2501–2508.
10. [10] Bastiaannet, E., Sampieri, K., Dekkers, O.M., de Craen, A.J., van Herk-Sukel, M.P., Lemmens, V., et al. Use of Aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer, 2012.
11. [11] Cardwell, C.R., Kunzmann, A.T., Cantwell, M.M., Hughes, C., Baron, J.A., Powe, D.G., et al. Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort. Gastroenterology, 146(700–8), 2014, e2.
12. [12] Chan, A.T., Ogino, S., Fuchs, C.S., Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302 (2009), 649–658.
13. [13] Coghill, A.E., Newcomb, P.A., Campbell, P.T., Burnett-Hartman, A.N., Adams, S.V., Poole, E.M., et al. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut 60 (2011), 491–498.
14. [14] Din, F.V., Theodoratou, E., Farrington, S.M., Tenesa, A., Barnetson, R.A., Cetnarskyj, R., et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 59 (2010), 1670–1679.
15. [15] Domingo, E., Church, D.N., Sieber, O., Ramamoorthy, R., Yanagisawa, Y., Johnstone, E., et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol 31 (2013), 4297–4305.
16. [16] Goh, C.H., Leong, W.Q., Chew, M.H., Pan, Y.S., Tony, L.K., Chew, L., et al. Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer. Anticancer Res 34 (2014), 7407–7414.
17. [17] Jacobs, E.J., Newton, C.C., Gapstur, S.M., Thun, M.J., Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst 104 (2012), 1208–1217.
18. [18] Liao, X., Lochhead, P., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367 (2012), 1596–1606.
19. [19] McCowan, C., Munro, A.J., Donnan, P.T., Steele, R.J., Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer 49 (2013), 1049–1057.
20. [20] Ng, K., Meyerhardt, J.A., Chan, A.T., Sato, K., Chan, J.A., Niedzwiecki, D., et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst, 107, 2015, 345.
21. [21] Reimers, M.S., Bastiaannet, E., Langley, R.E., van Eijk, R., van Vlierberghe, R.L., Lemmens, V.E., et al. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med 174 (2014), 732–739.
22. [22] Sun, R., Nishihara, R., Qian, Z.R., Chan, A.T., Ogino, S., Aspirin and colorectal cancer incidence and mortality by CTNNB1 expression: a molecular pathological epidemiology (MPE) study. Cancer Epidemiol Biomark Prev 22 (2013), 472–473.
23. [23] Walker, A.J., Grainge, M.J., Card, T.R., Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. Br J Cancer 107 (2012), 1602–1607.
24. [24] Zanders, M.M., van Herk-Sukel, M.P., Vissers, P.A., Herings, R.M., Haak, H.R., van de Poll-Franse, L.V., Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?. Br J Cancer 113 (2015), 403–410.
25. [25] Fuchs, C., Meyerhardt, J.A., Heseltine, D.L., Niedzwiecki, D., Hollis, D., Chan, A.T., et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from intergroup trial CALGB 89803 [Abstract]. J Clin Oncol, 23, 2005.
26. [26] Zell, J.A., Ziogas, A., Bernstein, L., Clarke, C.A., Deapen, D., Largent, J.A., et al. Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer 115 (2009), 5662–5671.
27. [27] Elwood, P.C., Gallagher, A.M., Duthie, G.G., Mur, L.A., Morgan, G., Aspirin, salicylates, and cancer. Lancet 373 (2009), 1301–1309.
28. [28] van Kruijsdijk, R.C., Visseren, F.L., Ridker, P.M., Dorresteijn, J.A., Buring, J.E., van der Graaf, Y., et al. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women. Heart 101 (2015), 369–376.
29. [29] Langley, R.E., Burdett, S., Tierney, J.F., Cafferty, F., Parmar, M.K., Venning, G., Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?. Br J Cancer 105 (2011), 1107–1113.
30. [30] Chia, W.K., Ali, R., Toh, H.C., Aspirin as adjuvant therapy for colorectal cancer–reinterpreting paradigms. Nat Rev Clin Oncol 9 (2012), 561–570.
31. [31] Targownik, L.E., Suissa, S., Understanding and avoiding immortal-time bias in gastrointestinal observational research. Am J Gastroenterol 110 (2015), 1647–1650.
32. [32] Stricker, B.H., Stijnen, T., Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol 25 (2010), 245–251.
33. [33] Suissa, S., Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167 (2008), 492–499.
34. [34] Austin, P.C., Mamdani, M.M., van Walraven, C., Tu, J.V., Quantifying the impact of survivor treatment bias in observational studies. J Eval Clin Pract 12 (2006), 601–612.
35. [35] Suissa, S., Azoulay, L., Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35 (2012), 2665–2673.
36. [36] Assayag, J., Pollak, M.N., Azoulay, L., The use of aspirin and the risk of mortality in patients with prostate cancer. J Urol 193 (2015), 1220–1225.
37. [37] van Walraven, C., Davis, D., Forster, A.J., Wells, G.A., Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol 57 (2004), 672–682.
38. [38] The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology; 2010.
39. [39] Wu, J.W., Boudreau, D.M., Park, Y., Simonds, N.I., Freedman, A.N., Commonly used diabetes and cardiovascular medications and cancer recurrence and cancer-specific mortality: a review of the literature. Expert Opin Drug Saf 13 (2014), 1071–1099.
40. [40] Chubak, J., Boudreau, D.M., Wirtz, H.S., McKnight, B., Weiss, N.S., Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst 105 (2013), 1456–1462.
41. [41] Csizmadi, I., Collet, J.-P., Bias and confounding in pharmacoepidemiology. Textbook of pharmacoepidemiology, 2006, John Wiley & Sons, Ltd., 261–275.
42. [42] Kyriacou, D.N., Lewis, R.J., Confounding by indication in clinical research. JAMA 316 (2016), 1818–1819.
43. [43] Vandenbroucke, J.P., When are observational studies as credible as randomised trials?. Lancet 363 (2004), 1728–1731.
44. [44] Larson, R.J., Fisher, E.S., Should aspirin be continued in patients started on warfarin?. J Gen Intern Med 19 (2004), 879–886.
45. [45] Dentali, F., Douketis, J.D., Lim, W., Crowther, M., Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 167 (2007), 117–124.
46. [46] Hansen, M.L., Sorensen, R., Clausen, M.T., Fog-Petersen, M.L., Raunso, J., Gadsboll, N., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170 (2010), 1433–1441.
47. [47] Jonsson, F., Yin, L., Lundholm, C., Smedby, K.E., Czene, K., Pawitan, Y., Low-dose aspirin use and cancer characteristics: a population-based cohort study. Br J Cancer 109 (2013), 1921–1925.
48. [48] Rothwell, P.M., Fowkes, F.G., Belch, J.F., Ogawa, H., Warlow, C.P., Meade, T.W., Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377 (2011), 31–41.
49. [49] Maity, G., De, A., Das, A., Banerjee, S., Sarkar, S., Banerjee, S.K., Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition. Lab Invest 95 (2015), 702–717.
50. [50] Mora, S., Manson, J.E., Aspirin for primary prevention of atherosclerotic cardiovascular disease: advances in diagnosis and treatment. JAMA Intern Med 176 (2016), 1195–1204.
51. [51] Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009), 1849–1860.
52. [52] Puhan, M.A., Yu, T., Stegeman, I., Varadhan, R., Singh, S., Boyd, C.M., Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer. BMC Med, 13, 2015, 250.
53. [53] Koene, R.J., Prizment, A.E., Blaes, A., Konety, S.H., Shared risk factors in cardiovascular disease and cancer. Circulation 133 (2016), 1104–1114.
54. [54] Sarfati, D., Hill, S., Blakely, T., Robson, B., Purdie, G., Dennett, E., et al. The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study. BMC Cancer, 9, 2009, 116.
55. [55] Sogaard, M., Thomsen, R.W., Bossen, K.S., Sorensen, H.T., Norgaard, M., The impact of comorbidity on cancer survival: a review. Clin Epidemiol 5 (2013), 3–29.
56. [56] Erichsen, R., Horvath-Puho, E., Iversen, L.H., Lash, T.L., Sorensen, H.T., Does comorbidity interact with colorectal cancer to increase mortality? A nationwide population-based cohort study. Br J Cancer 109 (2013), 2005–2013.
57. [57] Janssen-Heijnen, M.L., Szerencsi, K., van de Schans, S.A., Maas, H.A., Widdershoven, J.W., Coebergh, J.W., Cancer patients with cardiovascular disease have survival rates comparable to cancer patients within the age-cohort of 10 years older without cardiovascular morbidity. Crit Rev Oncol Hematol 76 (2010), 196–207.
58. [58] Bayliss, E., Reifler, L., Zeng, C., McQuillan, D., Ellis, J., Steiner, J., Competing risks of cancer mortality and cardiovascular events in individuals with multimorbidity. J Comorbidity 4 (2014), 29–36.
59. [59] van Erning, F.N., van Steenbergen, L.N., Lemmens, V.E., Rutten, H.J., Martijn, H., van Spronsen, D.J., et al. Conditional survival for long-term colorectal cancer survivors in the Netherlands: who do best?. Eur J Cancer 50 (2014), 1731–1739.
60. [60] Rothwell, P.M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C.P., et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376 (2010), 1741–1750.
61. [61] Jorgensen, T.L., Hallas, J., Friis, S., Herrstedt, J., Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer 106 (2012), 1353–1360.
62. [62] Extermann, M., Interaction between comorbidity and cancer. Cancer Control 14 (2007), 13–22.
63. [63] Coebergh, J.W., Janssen-Heijnen, M.L., Post, P.N., Razenberg, P.P., Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993–1996. J Clin Epidemiol 52 (1999), 1131–1136.
64. [64] Janssen-Heijnen, M.L., Houterman, S., Lemmens, V.E., Louwman, M.W., Maas, H.A., Coebergh, J.W., Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 55 (2005), 231–240.
65. [65] Rothwell, P.M., Price, J.F., Fowkes, F.G., Zanchetti, A., Roncaglioni, M.C., Tognoni, G., et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet, 2012.
66. [66] Rothwell, P.M., Wilson, M., Price, J.F., Belch, J.F.F., Meade, T.W., Mehta, Z., Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379 (2012), 1591–1601.
67. [67] Chubak, J., Whitlock, E.P., Williams, S.B., Kamineni, A., Burda, B.U., Buist, D.S., et al. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. preventive services task force. Ann Intern Med 164 (2016), 814–825.
68. [68] Cook, N.R., Lee, I.M., Zhang, S.M., Moorthy, M.V., Buring, J.E., Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 159 (2013), 77–85.
69. [69] Algra, A.M., Rothwell, P.M., Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol, 2012.
70. [70] Lipton, A., Scialla, S., Harvey, H., Dixon, R., Gordon, R., Hamilton, R., et al. Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer. J Med 13 (1982), 419–429.
71. [71] Burn, J., Mathers, J.C., Bishop, D.T., Chemoprevention in Lynch syndrome. Fam Cancer 12 (2013), 707–718.
72. [72] Murphy, C., Turner, N., Wong, H.L., Sinnathamby, M., Tie, J., Lee, B., et al. Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer. Intern Med J, 2016.
73. [73] ATCG. Website Aspirin Trialist Collaborative Group; 2016.
74. [74] Ogino, S., Nishihara, R., VanderWeele, T.J., Wang, M., Nishi, A., Lochhead, P., et al. Review article: the role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology 27 (2016), 602–611.
75. [75] Hemkens, L.G., Contopoulos-Ioannidis, D.G., Ioannidis, J.P., Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey. BMJ, 352, 2016, i493.
76. [76] Cole, B.F., Logan, R.F., Halabi, S., Benamouzig, R., Sandler, R.S., Grainge, M.J., et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101 (2009), 256–266.
77. [77] Guillem-Llobat, P., Dovizio, M., Bruno, A., Ricciotti, E., Cufino, V., Sacco, A., et al. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget, 2016.